
**Health informatics — Identification
of medicinal products — Data
elements and structures for the
unique identification and exchange
of regulated medicinal product
information**

*Informatique de santé — Identification des médicaments — Éléments
de données et structures pour l'identification unique et l'échange
d'informations sur les médicaments contrôlés*





COPYRIGHT PROTECTED DOCUMENT

© ISO 2017, Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Ch. de Blandonnet 8 • CP 401
CH-1214 Vernier, Geneva, Switzerland
Tel. +41 22 749 01 11
Fax +41 22 749 09 47
copyright@iso.org
www.iso.org

Contents

Page

Foreword	vi
Introduction	vii
1 Scope	1
2 Normative references	1
3 Terms, definitions and abbreviated terms	2
4 Message exchange format	13
5 Conformance terminology and context as it relates to the ISO IDMP standards and corresponding IDMP technical specifications	14
6 Concepts required for the unique identification of Medicinal Products	14
6.1 General considerations	14
6.2 Authorised Medicinal Products	14
6.3 Investigational Medicinal Products	15
6.4 Concepts required for the unique identification of a Medicinal Product and the association with PhPID(s)	15
6.5 Concepts required for the unique identification of Medicinal Products and the association with the marketing authorisation number	15
6.6 Concepts required for the unique identification of Medicinal Products and the association with data carrier identifiers	16
7 Description of the information modelling principles and practices	17
7.1 General considerations	17
7.2 Conceptual overview diagrams	17
7.3 High-level diagrams	18
7.4 Detailed description diagrams	18
7.4.1 General	18
7.4.2 Relationships between classes	19
7.4.3 Attributes of classes	20
7.4.4 Generalised classes and patterns	20
7.4.5 Translation and language	20
8 Identifying characteristics for authorised Medicinal Products	20
8.1 Primary identifiers — General considerations	20
8.2 Medicinal Product Identifier (MPID)	21
8.2.1 General considerations	21
8.2.2 MPID code segments	21
8.3 Packaged Medicinal Product Identifier (PCID)	22
8.3.1 General considerations	22
8.3.2 Package description (PCID) code segment	23
8.4 Medicinal Product Batch Identifier (BAID1)	23
8.5 Medicinal Product Batch Identifier (BAID2)	23
9 Information for an authorised Medicinal Product	24
9.1 Authorised Medicinal Product — Information overview	24
9.1.1 General	24
9.1.2 Medicinal Product	24
9.1.3 Medicinal Product name	24
9.1.4 Header	25
9.1.5 Manufacturer/Establishment (organisation)	25
9.1.6 Marketing authorisation	25
9.1.7 Packaged Medicinal Product	25
9.1.8 Pharmaceutical product	25
9.1.9 Ingredient	25
9.1.10 Clinical particulars	25
9.2 Medicinal Product	25

9.2.1	General.....	25
9.2.2	Detailed description of Medicinal Product information.....	26
9.3	Marketing authorisation.....	32
9.3.1	General.....	32
9.3.2	Detailed description of marketing authorisation information.....	33
9.4	Organisation.....	38
9.4.1	General.....	38
9.4.2	Detailed description of organisation information.....	38
9.5	Manufacturer/Establishment (organisation).....	41
9.5.1	General.....	41
9.5.2	Detailed description of manufacturer/establishment (organisation) information.....	41
9.6	Packaged Medicinal Product, including manufactured item and device.....	42
9.6.1	General.....	42
9.6.2	Detailed description of Packaged Medicinal Product information.....	43
9.7	Ingredient, substance and strength.....	52
9.7.1	General.....	52
9.7.2	Detailed description of ingredients, substance and strength information.....	52
9.8	Pharmaceutical product and device.....	55
9.8.1	General.....	55
9.8.2	Detailed description of pharmaceutical product and device information.....	55
9.9	Clinical particulars.....	57
9.9.1	General.....	57
9.9.2	Detailed description for clinical particulars information.....	58
10	Identifying characteristics for Investigational Medicinal Products.....	62
10.1	General.....	62
10.2	Primary identifiers.....	62
10.2.1	General considerations.....	62
10.3	Investigational Medicinal Product Identifier (IMPID).....	63
10.3.1	General considerations.....	63
10.3.2	IMPID code segments.....	63
10.4	Investigational Medicinal Product Package Identifier (IPCID).....	64
10.4.1	General provisions.....	64
10.4.2	Package description code segment.....	64
10.5	Investigational Medicinal Product Batch Identifier (BAID1).....	65
10.6	Investigational Medicinal Product Batch Identifier (BAID2).....	65
11	Information for an Investigational Medicinal Product.....	65
11.1	General.....	65
11.2	Conceptual overview of the information for an Investigational Medicinal Product.....	65
11.2.1	General.....	65
11.2.2	Investigational Medicinal Product.....	66
11.2.3	Investigational Medicinal Product name.....	66
11.2.4	Header.....	66
11.2.5	Manufacturer/Establishment (organisation).....	66
11.2.6	Clinical trial authorisation.....	67
11.2.7	Investigational Packaged Medicinal Product.....	67
11.2.8	Pharmaceutical product.....	67
11.2.9	Ingredient.....	67
11.2.10	Clinical particulars.....	67
11.3	Investigational Medicinal Product.....	67
11.3.1	General.....	67
11.3.2	Detailed description of Investigational Medicinal Product information.....	67
11.4	Clinical trial authorisation.....	70
11.4.1	General.....	70
11.4.2	Detailed description of clinical trial authorisation information.....	70
11.5	Manufacturer/Establishment (organisation).....	72
11.6	Investigational Packaged Medicinal Product.....	72

11.7	Pharmaceutical product.....	72
11.7.1	General.....	72
11.7.2	Pharmaceutical product.....	73
11.7.3	Dosing and route of administration.....	73
11.8	Ingredient.....	73
11.9	Clinical particulars.....	74
11.10	PhPID sets.....	74
11.11	Device nomenclature.....	74
11.12	Device batch identifier.....	74
11.13	Physical characteristics.....	74
11.14	Other characteristics.....	74
Annex A (normative) Full model — Authorised Medicinal Products detailed diagram.....		75
Annex B (normative) Full model — Investigational Medicinal Products detailed diagram.....		76
Bibliography.....		77

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 215, *Health informatics*.

This second edition cancels and replaces the first edition (ISO 11615:2012), which has been technically revised.

Introduction

This document was developed in response to a worldwide demand for internationally harmonised specifications for Medicinal Products. It is part of a set of five ISO Standards and four ISO Technical Specifications which together provide the basis for the unique Identification of Medicinal Products (IDMP).

These sets of standards and technical specifications comprise:

- ISO 11615
- ISO/TS 20443;
- ISO 11616;
- ISO/TS 20451;
- ISO 11238;
- ISO/TS 19844;
- ISO 11239;
- ISO/TS 20440;
- ISO 11240.

These standards and technical specifications for the identification of Medicinal Products (IDMP) support the activities of medicines regulatory agencies worldwide by region. These include a variety of regulatory activities related to development, registration and life cycle management of Medicinal Products, as well as pharmacovigilance and risk management.

To meet the primary objectives of the regulation of medicines and pharmacovigilance, it is necessary to reliably exchange Medicinal Product information in a robust and consistent manner. The IDMP standards therefore support, at a minimum, the following interactions:

- regulatory medicines authority to regulatory medicines authority;
- pharmaceutical company to regulatory medicines authority;
- sponsor of a clinical trial to regulatory medicines authority;
- regulatory medicines authority to other stakeholders (as applicable);
- regulatory medicines authority to worldwide-maintained data sources.

The necessary messaging specifications are included as an integral part of the IDMP standards to secure the interactions above.

Unique identifiers produced in conformance with the IDMP standards are aimed at supporting applications where it is necessary to reliably identify and trace the use of Medicinal Products.

There are many terms in use to describe basic concepts in the regulatory, pharmaceutical and healthcare standards development domain for different purposes and in different contexts. The terms and definitions given in this document are to be applied for the concepts which are required to uniquely identify, characterise and exchange regulated Medicinal Products and associated information.

The terms and definitions adopted in this document are intended to facilitate the interpretation and application of legal and regulatory requirements.

This document has been developed in conjunction with the Common Product Model (CPM) and Structured Product Labelling (SPL) in HL7.

In the context of exchange of regulatory information, the purpose of this document is twofold:

- to specify data elements, structures and relationships between the data elements which are required to uniquely and with certainty identify Medicinal Products for human use;
- to specify definitions of terms for all data elements required to uniquely and with certainty identify Medicinal Products for human use.

In addition, reference to the use of other normative IDMP and messaging standards for Medicinal Product information is included in this document in order to support successful information exchange.

Health informatics — Identification of medicinal products — Data elements and structures for the unique identification and exchange of regulated medicinal product information

1 Scope

This document establishes definitions and concepts and describes data elements and their structural relationships, which are required for the unique identification and the detailed description of Medicinal Products.

Taken together, the standards listed in the Introduction define, characterise and uniquely identify regulated Medicinal Products for human use during their entire life cycle, i.e. from development to authorisation, post-marketing and renewal or withdrawal from the market, where applicable.

Furthermore, to support successful information exchange in relation to the unique identification and characterisation of Medicinal Products, the use of other normative IDMP messaging standards is included, which are to be applied in the context of this document.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 639-1, *Codes for the representation of names of languages — Part 1: Alpha-2 code*

ISO 3166-1:2013, *Codes for the representation of names of countries and their subdivisions — Part 1: Country codes*

ISO 8601, *Data elements and interchange formats — Information interchange — Representation of dates and times*

ISO 11238, *Health informatics — Identification of Medicinal Products — Data elements and structures for the unique identification and exchange of regulated information on substances*

ISO 11239, *Health informatics — Identification of Medicinal Products — Data elements and structures for the unique identification and exchange of regulated information on pharmaceutical dose forms, units of presentation, routes of administration and packaging*

ISO 11240, *Health informatics — Identification of Medicinal Products — Data elements and structures for the unique identification and exchange of units of measurement*

ISO 11616, *Health informatics — Identification of Medicinal Products — Data elements and structures for the unique identification and exchange of regulated pharmaceutical product information*

ISO/TS 19844, *Health informatics — Identification of Medicinal Products — Implementation guidelines for data elements and structures for the unique identification and exchange of regulated information on substances*

ISO/TS 20440, *Health informatics — Identification of Medicinal Products — Implementation guide for ISO 11239 data elements and structures for the unique identification and exchange of regulated information on pharmaceutical dose forms, units of presentation, routes of administration and packaging*